MISSISSAUGA, ON, Sept. 26, 2011 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology
and cancer-related products, today announced that data from several
clinical trials of nimotuzumab are scheduled be reported at the 2011
European Multidisciplinary Cancer Congress (ECCO-ESMO), September
23-27, 2011, in Stockholm, Sweden.
A poster presentation entitled "Phase 2 study of nimotuzumab in
combination with concurrent chemoradiotherapy (CRT) in patients with
locally advanced non-small cell lung cancer (NSCLC)" is scheduled to be
presented at the poster session "Lung Cancer-Localised/Local Regional"
on Monday, September 26th, 2011 from 14:00 to 16:30pm (Abstract No.
9044; Poster Board 033).
A poster presentation entitled "Nimotuzumab and Vinorelbine
Concomitantly to Radiation and as Maintenance for Diffuse Pontine
Glioma in Childhood: Promising Results on a Series of 13 Patients" is
scheduled to be presented at the poster session "Paediatric Oncology"
on Sunday, September 25th, 2011 from 14:00 to 16:30pm (Abstract No.
4125; Poster Board 408).
A poster presentation entitled "Nimotuzumab in Combination with
Chemotherapy in the Patients with Advanced Non-small Cell Lung Cancer"
is scheduled to be presented at the poster session "Lung
Cancer-Metastatic" on Monday, September 26th, 2011 from 14:00 to
16:30pm (Abstract No. 9124; Poster Board 113).
A poster presentation entitled "Pilot Study of Target Therapy With EGFR
Antibody (Nimotuzumab) in Patients With Unresectable Head and Neck
Cancer" is scheduled to be presented at the poster session "Head and
Neck Cancer" on Sunday, September 25th, 2011 from 9:30am to 12:00pm
(Abstract No. 8588; Poster Board 081).
Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an
enhanced side effect profile over currently marketed EGFR-targeting
antibodies. Nimotuzumab reportedly has been approved in 27 countries
and more than 15,500 patients have been treated with the drug to date
in 35 countries.
Nimotuzumab is licensed to YM's majority-owned joint venture, CIMYM
BioSciences Inc., for Western and Eastern Europe, North America and
Japan, as well as Australia, New Zealand, Israel and certain Asian and
African countries. The drug is currently being evaluated in several
Phase II and III trials in these major markets by various licensees of
About YM BioSciences
YM BioSciences Inc. is a drug development company advancing three
clinical-stage products: CYT387, a small molecule, dual inhibitor of
the JAK1/JAK2 kinases; nimotuzumab, an EGFR-targeting monoclonal
antibody; and CYT997, a vascular disrupting agent (VDA).
CYT387 is an orally administered inhibitor of both the JAK1 and JAK2
kinases, which have been implicated in a number of immune cell
disorders including myeloproliferative neoplasms and inflammatory
diseases as well as certain cancers. CYT387 is currently in a Phase
I/II trial in myelofibrosis. Nimotuzumab is a humanized monoclonal
antibody targeting EGFR with an enhanced side-effect profile over
currently marketed EGFR-targeting antibodies. Nimotuzumab is being
evaluated in numerous Phase II and III trials worldwide. CYT997 is an
orally-available small molecule therapeutic with dual mechanisms of
vascular disruption and cytotoxicity, and has completed a Phase II
trial in glioblastoma multiforme. In addition to YM's three clinical
stage products, the Company has a library of novel compounds identified
through internal research conducted at YM BioSciences Australia.
This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may
cause actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by
such forward-looking statements. Such factors include, but are not
limited to, changing market conditions, the successful and timely
completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new product
development, uncertainties related to the regulatory approval process
or the ability to obtain drug product in sufficient quantity or at
standards acceptable to health regulatory authorities to complete
clinical trials or to meet commercial demand; and other risks detailed
from time to time in the Company's ongoing quarterly and annual
reporting. Certain of the assumptions made in preparing forward-looking
statements include but are not limited to the following: that CYT387,
nimotuzumab and CYT997 will generate positive efficacy and safety data
in ongoing and future clinical trials, and that YM and its various
partners will complete their respective clinical trials and disclose
data within the timelines communicated in this release. Except as
required by applicable securities laws, we undertake no obligation to
publicly update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
SOURCE YM BioSciences Inc.
For further information:
VP Corporate Communications
YM BioSciences Inc.
Tel. +1 905.361.9518